Upload
one-to-one
View
105
Download
1
Tags:
Embed Size (px)
DESCRIPTION
One to One Health and OTOinsights will share the results of a first-of-its-kind pharma neuromarketing study which moves user effectiveness research beyond the focus group or the and inevitable cognitive bias that results. The study, conducted using our proprietary Quantemo™ offering, examined not only how patients view but also neurologically react to and emotionally respond to pharmaceutical brand websites in a single therapeutic category (allergies). We will discuss the neurological, emotional, and eye tracking data collected and the implications that the results have on best practices for designing branded pharmaceutical websites.
Citation preview
1www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Beyond the Voice of the Customer: Neuromarketing Insights into Patient Engagement with Pharmaceutical Brand Web Sites
April 8, 2010
One to One Interactive, 2010. All rights reserved.
2www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Please Tweet About This Webinar!
@OnetoOneHealth@OTOinsights
#neuromarketing#allergymarketing#ePharma#ehealth
3www.otoihealth.com One to One Interactive, 2010. All rights reserved.
4www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Agenda
5www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Presenting Today
Seth Levine, Vice President/Director – One to One Health@silevine
Dan Berlin, Sr. Researcher – OTOinsights, a One to One Interactive company@banderlin
Jeremi Karnell, Co-founder & President – One to One Interactive@jkarnell
6www.otoihealth.com One to One Interactive, 2010. All rights reserved.
7www.otoihealth.com One to One Interactive, 2010. All rights reserved.
One to One Health is a specialized practice group within One to One Interactive dedicated to delivering innovative, transformational healthcare and life sciences marketing strategies, programs and creative. Building on a broad base of category experience (including pharmaceuticals, devices, health information and healthcare delivery) combined with deep interactive channel, digital media, CRM, and social media marketing experience, we help clients chart the right path for them in what we call the “Digital Health Information Ecosystem™.”
RadiologyCritical CareHIVTransplantEndocrinology
Sampling of Therapy and Focus Areas:
RespiratoryDigestivePainDiabetesMen’s Health
Psychiatric/Mood DisordersNeurological/CNSSTDsCardiovascularWoman’s Health
DiagnosticsHealthcare DeliveryHealth InformationHealth Field Sales SupportPharmacy
Sampling of Clients:
Offering Solutions for:
HospitalsHealth NetworksDevice/DiagnosticsHealth InformationPharmacy RetailWidgets/Mobile
Pharmaceuticals/BiotechDTC – Branded, UnbrandedProfessional/HCP
Lead Generation/eCRM/emailMedia – Display, Search, SocialResearch Organizations & Foundations
7
About One to One Health
www.otoihealth.com
8www.otoihealth.com One to One Interactive, 2010. All rights reserved.
OTOinsights | Amplifying Engagement
Brand Planning Information Design Neuromarketing Research
User Experience Research
• Eye-Tracking• Emotional Response• Neurological
Engagement
• Usability Testing• Focus Groups• In-Depth/Paired
Interviews• Online Surveys• Expert Evaluations• Accessibility Audits• Ethnographics
• Socially Informed/ Multi-Channel Personas• Engagement Mapping• Cultural Anthropology• Trend Spotting
• User Needs Analysis• Information Architecture• User Scenarios• Behavioral Use Cases• Feature Matrix• Wireframes• Site Maps• Prototype Development
9www.otoihealth.com One to One Interactive, 2010. All rights reserved.
10www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Purpose of this Webinar
Provide you with the fundamentals of neuromarketing
Explain what “engagement” is and it’s relevance to the performance of digital media
Discuss how marketers can use neuromarketing studies to remove cognitive bias inherent in traditional testing
Discuss how neuromarketing studies can be used to effectively evaluate creative performance before it’s in-market
Share the results of a first-of-its kind neuromarketing study done in the pharmaceutical space
11www.otoihealth.com One to One Interactive, 2010. All rights reserved.
12www.otoihealth.com One to One Interactive, 2010. All rights reserved.
13www.otoihealth.com One to One Interactive, 2010. All rights reserved.
14www.otoihealth.com One to One Interactive, 2010. All rights reserved.
15www.otoihealth.com One to One Interactive, 2010. All rights reserved.
16www.otoihealth.com One to One Interactive, 2010. All rights reserved.
17www.otoihealth.com One to One Interactive, 2010. All rights reserved.fMR
I
18www.otoihealth.com One to One Interactive, 2010. All rights reserved.
19www.otoihealth.com One to One Interactive, 2010. All rights reserved.EEG
20www.otoihealth.com One to One Interactive, 2010. All rights reserved.
21www.otoihealth.com One to One Interactive, 2010. All rights reserved.Bio
-Feed
back
22www.otoihealth.com One to One Interactive, 2010. All rights reserved.
23www.otoihealth.com One to One Interactive, 2010. All rights reserved.
24www.otoihealth.com One to One Interactive, 2010. All rights reserved.
25www.otoihealth.com One to One Interactive, 2010. All rights reserved.
26www.otoihealth.com One to One Interactive, 2010. All rights reserved.
27www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Quantemo Engagement Index (QEI) combines data from traditional user research, information processing models, and socio-cultural models to correlate people’s felt experience of their emotions when interacting with media stimuli with their behavioral/physiological responses.
Quantemo™ Engagement Index (QEI)
Σ = Quantemo Behavioral Index + Quantemo Neurological Index + Emotional Tagging + Likert Rating
28www.otoihealth.com One to One Interactive, 2010. All rights reserved.
29www.otoihealth.com One to One Interactive, 2010. All rights reserved.
30www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Overview of StudyIn this study, we compared participants’ levels of engagement with 8 static web pages from branded allergy medication web sites – both OTC and prescription brands
• Static web pages displayed in a random order• After all stimuli were shown, participants fill out emotional and rating surveys• Qualitative interview conducted• Participants were male and female, ages 25-55, current allergy suffers
31www.otoihealth.com One to One Interactive, 2010. All rights reserved.
OVERALL ENGAGEMENT
32www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Overall Engagement
Zyrtec
Claritin
Benedryl
Astepro
Xyzal
Astelin
Veramyst
Nasonex
-0.50
0.00
0.50
1.00
1.50
2.00
2.50
3.00
2.49
2.14
1.22
0.400.21
-0.05 -0.07-0.18
Quantemo Engagement Index
Site
QEI
• Multiple Calls to Action and navigations • Pleasing colors• OTC Status• Outdoor activity
• Page is mostly ISI• Single, lengthy
navigation• Single type of Call to
Action
33www.otoihealth.com One to One Interactive, 2010. All rights reserved.
The Elements of Engagement
Zyrtec Xyzal Nasonex Astepro Benedryl Claritin Astelin Veramyst0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40 1.33 1.33
1.12
0.730.67
0.59
0.230.15
Quantemo Neurological Index
Site
QN
I
Actionable insights gained by triangulating on the consumer experience
Xyzal had high neurological engagement, but low overall engagement
34www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Insight: The Elements of High & Low Engagement
High Engagement
OTC status People + Product Images ISI Toward Bottom Less Text Social Content Prominent Indication Prominent Messaging Areas Simple Navigation Choices
Low Engagement
– Rx status– Product Images Only– ISI Centrally Located– More Text– Patient Stories– Indication Not Prominent– Compact Messaging Areas– Complex Navigation Choices
35www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Insight: The Elements of High & Low Engagement
Over the counter pharmaceuticals have an advantage over prescription medications• Higher levels of overall engagement
Zyrtec Claritin Benedryl Astepro Xyzal Astelin Veramyst Nasonex-0.50
0.00
0.50
1.00
1.50
2.00
2.50
3.00
2.49
2.14
1.22
0.400.21
-0.05 -0.07-0.18
Quantemo Engagement Index
Site
QEI
36www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Claritin and ZyrtecOver the counter pharmaceuticals have an advantage over prescription medications• Higher levels of overall engagement• Claritin and Zyrtec had almost no associated negative emotions
37www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Insight: The Elements of High & Low EngagementConsumers had low neurological engagement with pages without a prominent human face• Consumers also expect to see an image of the product
Zyrtec Xyzal Nasonex Astepro Benedryl Claritin Astelin Veramyst0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40 1.33 1.33
1.12
0.730.67
0.59
0.230.15
Quantemo Neurological Index
Site
QN
I
38www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Astelin and Veramyst
Consumers had low neurological engagement with pages without a prominent human face• Consumers also expect to see an image of the product
Fold
Fold
39www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Insight: The Elements of High & Low Engagement
A prominently placed, lengthy ISI treatment can be detrimental to consumer engagement
FoldFold
40www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Insight: The Elements of High & Low Engagement
A prominent, text-heavy ISI section can be detrimental to consumer engagement
FoldFold
41www.otoihealth.com One to One Interactive, 2010. All rights reserved.
0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30sST Excitement LT Excitement Engagement
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Xyzal Neuro Traces over Time
Neurological Trace and Seconds
Perc
ent
Insight: The Elements of High & Low Engagement
A prominent, lengthy ISI treatment can be detrimental to consumer engagement
• For Xyzal, neurological excitement increases while users focus on Features and ISI• Time is split in the last 15 seconds between the bottom Feature and the ISI
16-30 seconds
42www.otoihealth.com One to One Interactive, 2010. All rights reserved.
0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30s 0s-5s 6s-15s 16s-30sST Excitement LT Excitement Engagement
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Nasonex Neuro Traces over Time
Neurological Trace and Seconds
Perc
ent
Insight: The Elements of High & Low Engagement
• For Nasonex, neurological excitement decreases while users focus on the navigation and ISI• Time is split in the last 15 seconds between the bottom Feature and the ISI
16-30 seconds
A prominent, lengthy ISI treatment can be detrimental to consumer engagement
43www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Insight Review: The Elements of High & Low Engagement
Over the counter pharmaceuticals have an advantage over prescription medications• Higher levels of overall engagement and Zyrtec’s high long-term excitement• Claritin and Zyrtec had almost no associated negative emotions
Consumers had low neurological engagement with pages without a prominent human face• Consumers also expect to see an image of the product
A prominent, text-heavy ISI section can be detrimental to consumer engagement
44www.otoihealth.com One to One Interactive, 2010. All rights reserved.
FEMALE VS. MALE ENGAGEMENT
45www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Female vs. Male Engagement
Xyzal had high neurological engagement, but low overall engagement
Zyrtec Xyzal Nasonex Astepro Benedryl Claritin Astelin Veramyst0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40 1.33 1.33
1.12
0.730.67
0.59
0.230.15
Quantemo Neurological Index
Site
QN
I
46www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Female vs. Male Engagement
Astelin Astepro Benedryl Claritin Nasonex Veramyst Xyzal Zyrtec0.00
0.50
1.00
1.50
2.00
2.50
Quantemo Neurological Index by Sex
Site
QN
I
Male Female
Women viewing Xyzal had the highest neurological engagement of all stimuli
Females, 16-30 seconds
47www.otoihealth.com One to One Interactive, 2010. All rights reserved.
EYE TRACKING MYTHBUSTERS:THE ALLERGY EDITION
48www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Eye Tracking Mythbusters: The Allergy Edition
16-30 seconds0-5 seconds 6-15 seconds
16-30 seconds
0-5 seconds
6-15 seconds
Fold
49www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Eye Tracking Mythbusters: The Allergy Edition
Myth 1: People don’t read headlines – BUSTED• They do - and users expect to quickly see the indication
Myth 2: People don’t read body copy – BUSTED• They do - and early on
Myth 3: People don’t look for nor do they read the ISI – BUSTED• They do read it… albeit later
50www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Eye Tracking Mythbusters: The Allergy Edition
0-5 seconds
Myth 1: People don’t read headlines – BUSTED• They do - and users expect to quickly see the indication
51www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Eye Tracking Mythbusters: The Allergy Edition
0-5 seconds 6-15 seconds
0-5 seconds 6-15 seconds
0-5 seconds 6-15 seconds
Myth 2: People don’t read body copy – BUSTED• They do - and early on
52www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Eye Tracking Mythbusters: The Allergy Edition
Not on AOI
Brand Logo
Top Nav1
HCP
Headline
FaceCopy
Feature
1
Feature
2 ISI
CoLogo1
CoLogo2
Site M
ap
Save CTA
Top Nav2
0
0.1
0.2
0.3
0.4
0.5
0.6
Xyzal Fixations per Second over Time
Area of Interest
Fixa
tions
per
Sec
ond
Not on AOI
Brand Logo
Top Nav
Nav
Headline
Copy
Product
Video CTA
Dr. CTA
Save CTA ISI
Site M
ap
Co Logos
0
0.1
0.2
0.3
0.4
0.5
Veramyst Fixations per Second over Time
Area of Interest
Fixa
tions
per
Sec
ond
Not on AOI
Brand Logo
Nav
Product
Headline
Face
Save CTACTA ISI
Co Logo
Site M
ap0
0.1
0.2
0.3
0.4
0.5
Nasonex Fixations per Second over Time
Area of Interest
Fixa
tions
per
Sec
ond
Not on AOI
Brand Logo
HCP
Top Nav
Product
Headline
Copy
Feature
Save CTA
Use CTA
Dr. CTA ISI
Site M
ap
Co Logo
0
0.1
0.2
0.3
0.4
0.5
Astepro Fixations per Second over Time
Area of Interest
Fixa
tions
per
Sec
ond
Not on AOI
Brand Logo
Top Nav
Headline
Product
Feature
Social C
TAHCP
Use CTA
Save CTA
Co Logo ISI
Site M
ap0
0.1
0.2
0.3
0.4
0.5
Astelin Fixations per Second over Time
Area of Interest
Fixa
tions
per
Sec
ond
6s-15s 16s-30s0s-5s
Myth 3: People don’t look for nor do they read the ISI – BUSTED• They do read it… albeit later
53www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Eye Tracking Mythbusters: The Allergy Edition
Fold
Myth 3: People don’t look for nor do they read the ISI – BUSTED• They do read it… albeit later
54www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Wrap Up
Methodologies and approach can be applied to any health or business vertical
Quantemo can be a critical part of brand planning, product launch, creative development and asset optimization efforts
Testing can be done on websites, landing pages, registration forms/buy flows, digital media, video, animation, email, games, kiosks and more…
Call us for a complementary consultation. Let us propose a study design that addresses your business needs and answers your most challenging questions
55www.otoihealth.com One to One Interactive, 2010. All rights reserved.
56www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Contact One to One Health & OTOinsights
Seth Levine – Vice President/Director One to One health
Email: [email protected]: +1-617-425-7319International: add 00 + 1Mobile: 617-331-0397Website: otoihealth.comBlog: RxforDigital.comTwitter: @otointeractive
David LaPlante – Sr. Vice President, Sales & Marketing
Email: [email protected]: +1-775-771-5404International: add 00 + 1Website: otoinsights.comBlog: otoinsights.comTwitter: @otoinsights
57www.otoihealth.com One to One Interactive, 2010. All rights reserved.
Upcoming One to One Interactive Webinar
April 15, 201011am ET & 2 pm ET (US)
How To Design Mobile Applications and Widgets That Will Connect Meaningfully with Your Customers
Visit http://bit.ly/mobileux for more information.
58www.otoihealth.com One to One Interactive, 2010. All rights reserved.